Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 21 · above the Ichimoku cloud · RSI 54 · MACD below its signal
| 16.33 | 52-week high | +16.23% |
| 14.93 | Previous month high | +6.26% |
| 14.43 | R3 (classic) | +2.73% |
| 14.36 | R2 (classic) | +2.18% |
| 14.28 | Previous day high | +1.64% |
| 14.28 | Previous week high | +1.64% |
| 14.20 | R1 (classic) | +1.09% |
| 14.13 | Pivot | +0.55% |
| 14.05 | Previous day low | +0.00% |
| 14.05 | Price now | |
| 13.97 | S1 (classic) | −0.55% |
| 13.90 | S2 (classic) | −1.09% |
| 13.74 | S3 (classic) | −2.18% |
| 13.28 | Previous week low | −5.48% |
| 11.80 | Previous month low | −16.01% |
| 9.77 | 52-week low | −30.46% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.4M | 0.00% | 130.20K | −1.4% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a HCM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for HCM.
TimeframesUp on the hourly, down on the monthly, mixed on the daily and weekly.
over a rising 21 EMA, 21 over 50
over a flat 21 EMA
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 12.5 | -4.5 | 4.4 | -10.2 | -14.8 | -6.0 | 3.4 | 8.9 | 20.7 | -4.0 | +5.4% | ||
| 2025 | -6.2 | 21.7 | -8.6 | -1.3 | -6.5 | 8.4 | 18.1 | -15.6 | 4.9 | -6.8 | -1.8 | -7.6 | −7.5% |
| 2024 | -31.0 | 20.9 | 11.2 | 10.2 | 0.1 | -7.6 | 13.6 | -10.2 | 11.9 | -7.8 | -5.8 | -15.0 | −20.4% |
| 2023 | 21.9 | -8.2 | -21.3 | 17.1 | -21.3 | 0.0 | 17.2 | 6.8 | 12.8 | 15.0 | -1.0 | -6.1 | +22.5% |
| 2022 | -22.3 | 0.0 | -30.6 | -20.2 | -30.3 | 20.2 | 3.4 | -1.6 | -31.1 | -0.2 | 37.2 | 21.8 | −57.9% |
| 2021 | -0.3 | -9.9 | -1.7 | 0.1 | 5.2 | 32.0 | 7.1 | -4.0 | -9.3 | -19.6 | 15.1 | 3.6 | +9.6% |
| 2020 | -2.1 | -5.0 | -23.5 | 20.5 | 1.4 | 26.5 | -1.7 | 22.5 | -2.8 | -8.9 | 5.3 | 3.3 | +27.7% |
| 2019 | -1.7 | 14.9 | 17.2 | -1.6 | -8.2 | -20.3 | -5.0 | 4.2 | -18.1 | 5.9 | 27.6 | 4.0 | +8.6% |
| 2018 | -5.4 | -9.8 | -12.2 | 15.2 | -14.5 | 3.6 | 5.4 | -7.9 | 10.0 | 1.8 | 5.2 | -33.0 | −41.4% |
| 2017 | 3.8 | -9.6 | 56.6 | -2.3 | 8.9 | 9.8 | -5.0 | 13.5 | 8.4 | 11.7 | 13.6 | 14.0 | +190.5% |
| 2016 | -0.8 | -4.4 | 5.0 | -0.2 | -5.2 | -4.4 | 1.3 | 14.8 | -2.0 | +2.8% |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Buy / hold / sell counts